Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
PSG Stock Overview
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany.
PharmaSGP Holding Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €24.20 |
52 Week High | €27.00 |
52 Week Low | €18.05 |
Beta | 0 |
1 Month Change | 3.42% |
3 Month Change | 6.14% |
1 Year Change | 7.08% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -29.85% |
Recent News & Updates
PharmaSGP Holding SE Just Beat Revenue Estimates By 25%
It's been a good week for PharmaSGP Holding SE ( ETR:PSG ) shareholders, because the company has just released its...
Shareholder Returns
PSG | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -0.4% | 3.8% | 2.2% |
1Y | 7.1% | 21.7% | -11.9% |
Return vs Industry: PSG underperformed the German Pharmaceuticals industry which returned 21.7% over the past year.
Return vs Market: PSG exceeded the German Market which returned -11.9% over the past year.
Price Volatility
PSG volatility | |
---|---|
PSG Average Weekly Movement | 4.4% |
Pharmaceuticals Industry Average Movement | 6.5% |
Market Average Movement | 6.2% |
10% most volatile stocks in DE Market | 10.8% |
10% least volatile stocks in DE Market | 3.4% |
Stable Share Price: PSG is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PSG's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 66 | Natalie Weigand | https://pharmasgp.com |
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments.
PharmaSGP Holding Fundamentals Summary
PSG fundamental statistics | |
---|---|
Market Cap | €290.40m |
Earnings (TTM) | €10.69m |
Revenue (TTM) | €65.34m |
27.2x
P/E Ratio4.4x
P/S RatioIs PSG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PSG income statement (TTM) | |
---|---|
Revenue | €65.34m |
Cost of Revenue | €6.49m |
Gross Profit | €58.86m |
Other Expenses | €48.17m |
Earnings | €10.69m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 0.89 |
Gross Margin | 90.07% |
Net Profit Margin | 16.36% |
Debt/Equity Ratio | 0% |
How did PSG perform over the long term?
See historical performance and comparisonValuation
Is PharmaSGP Holding undervalued compared to its fair value and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PSG (€24.2) is trading below our estimate of fair value (€60.23)
Significantly Below Fair Value: PSG is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PSG is poor value based on its Price-To-Earnings Ratio (27.2x) compared to the German Pharmaceuticals industry average (24.3x).
PE vs Market: PSG is poor value based on its Price-To-Earnings Ratio (27.2x) compared to the German market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: PSG is poor value based on its PEG Ratio (2.3x)
Price to Book Ratio
PB vs Industry: PSG is overvalued based on its Price-To-Book Ratio (13.1x) compared to the DE Pharmaceuticals industry average (2.6x).
Future Growth
How is PharmaSGP Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
11.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PSG's forecast earnings growth (11.6% per year) is above the savings rate (-0.05%).
Earnings vs Market: PSG's earnings (11.6% per year) are forecast to grow faster than the German market (8.1% per year).
High Growth Earnings: PSG's earnings are forecast to grow, but not significantly.
Revenue vs Market: PSG's revenue (9.8% per year) is forecast to grow faster than the German market (4.7% per year).
High Growth Revenue: PSG's revenue (9.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PSG's Return on Equity is forecast to be very high in 3 years time (42.7%).
Past Performance
How has PharmaSGP Holding performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-11.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PSG has a high level of non-cash earnings.
Growing Profit Margin: PSG's current net profit margins (16.4%) are lower than last year (16.8%).
Past Earnings Growth Analysis
Earnings Trend: PSG's earnings have declined by 11.1% per year over the past 5 years.
Accelerating Growth: PSG's earnings growth over the past year (0.5%) exceeds its 5-year average (-11.1% per year).
Earnings vs Industry: PSG earnings growth over the past year (0.5%) underperformed the Pharmaceuticals industry 17.7%.
Return on Equity
High ROE: PSG's Return on Equity (48.2%) is considered outstanding.
Financial Health
How is PharmaSGP Holding's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: PSG's short term assets (€32.5M) do not cover its short term liabilities (€92.7M).
Long Term Liabilities: PSG's short term assets (€32.5M) exceed its long term liabilities (€334.0K).
Debt to Equity History and Analysis
Debt Level: PSG is debt free.
Reducing Debt: PSG had no debt 5 years ago.
Debt Coverage: PSG has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: PSG has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is PharmaSGP Holding current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
2.10%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PSG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PSG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PSG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PSG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PSG has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.2yrs
Average board tenure
CEO
Natalie Weigand (40 yo)
1.92yrs
Tenure
€272,000
Compensation
Ms. Natalie Weigand is Chief Executive Officer of PharmaSGP Holding SE since June 2020 and also serves as its Member of Management Board. She joined the FUTRUE Group as the leader of strategic marketing in...
CEO Compensation Analysis
Compensation vs Market: Natalie's total compensation ($USD291.41K) is below average for companies of similar size in the German market ($USD890.29K).
Compensation vs Earnings: Natalie's compensation has been consistent with company performance over the past year.
Board Members
Experienced Board: PSG's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
PharmaSGP Holding SE's employee growth, exchange listings and data sources
Key Information
- Name: PharmaSGP Holding SE
- Ticker: PSG
- Exchange: XTRA
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €290.400m
- Shares outstanding: 12.00m
- Website: https://pharmasgp.com
Number of Employees
Location
- PharmaSGP Holding SE
- Lochhamer Schlag 21
- Gräfelfing
- Bavaria
- 82166
- Germany
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/28 00:00 |
End of Day Share Price | 2022/05/27 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.